SUZHOU, China, May 8, 2023 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that two posters for clinical trials of its ADCC enhanced anti-CLDN18.2 monoclonal antibody Osemitamab (TST001) in combination with CAPOX or CAPOX plus Nivolumab for first-line G/GEJ cancer will be presented at 2023 American Society of Clinical Oncology (“ASCO”) Annual Meeting.

SUZHOU, China, Mar.23, 2023, Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announces that two preclinical studies in relation to TST003, a First-in-Class mAb Targeting GREMLIN-1, and TST010, an ADCC enhanced anti-CD25 mAb will be presented as posters at the American Association for Cancer Research (AACR) Annual Meeting 2023. This year’s meeting will be held from April 14-19, 2023, in Orlando, Florida, USA.

SUZHOU, China, Jan. 18, 2023, Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it will present the design of 2 cohorts from a Phase I/IIa study of TST001, its high affinity humanized ADCC-enhanced anti-Claudin18.2 monoclonal antibody, in combination with Nivolumab plus Capecitabine and Oxaliplatin as first-line or with Nivolumab as late-line treatment in locally advanced and metastatic gastric/gastroesophageal junction (G/GEJ) cancer (TranStar102/TST001-1002).

Oct 24, 2022, Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that Transcenta is invited to participate the 10th TEMTIA meeting in Paris, France, November 7 to 10and present preclinical data of TST003, Transcenta’s first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1.

SUZHOU, China, Oct. 14, 2022, Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it will present two scientific posters at the 37th Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in Boston, MA, November 8-12, 2022: one related to Claudin18.2 and PD-L1 expression in gastric/gastro-esophageal adenocarcinoma, relevant for TST001 (Osemitamab) clinical development and the other on TST005 (PD-L1/TGF-β bifunctional antibody) trial in progress.

SUZHOU, China, July 28, 2022 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the interim safety and efficacy data of dose expansion cohort from the phase I study of TST001, a humanized anti-Claudin18.2 monoclonal antibody, in combination with Capecitabine and Oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer will be presented at the European Society for Medical Oncology (ESMO) Congress 2022, which will be held on September 9-13, 2022. Details will be provided upon Embargo release later.